Drug Trial Radar · NCT06159504
Simplifying Hepatitis C Pathways for People Who Inject Drugs in Armenia, Georgia, and Tanzania
Last checked: Nov 19, 2026Latest source record: Oct 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
3,040
Planned (sponsor's estimate)
Start
Oct 3, 2024
Primary completion
Dec 2026
Study completion Dec 2026
Sponsor
- Lead sponsor
- Médecins du MondeAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- UNITAID; Burnet Institute; University of Bristol; International Network of People who Use Drugs
- First posted
- Dec 6, 2023
Design
- Study type
- Interventional
- Phase
- Early phase 1
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this non-randomised, quasi-experimental, prospective comparative trial is to trial simplified care pathways for hepatitis C testing and treatment for people who inject drugs in Armenia, Georgia, and Tanzania. The main questions it aims to answer are: 1. What is the feasibility of implementing a hepatitis C simplified care and same-day treatment care model in community and harm reduction settings in the three study countries? 2. Does a same-day treatment initiation model involving only POC antibody tests (with a shortened read-time) increase hepatitis C treatment uptake and SVR12 outcome (cure) among people who inject drugs compared with a simplified care model involving POC antibody followed by a confirmatory RNA test? 3. What is the comparative cost-effectiveness between a same-day antibody only hepatitis C testing and treatment model and the simplified care model (POC antibody/confirmatory RNA test) model? Participants will: * be enrolled in a new simplified model of care in each country (Arm 1). After the enrolment target is met for Arm 1 (approx. 3-9 months into implementation) new participants will be enrolled into a same-day treatment trial, using presumptive treatment after a reactive POC test result at shortened read-time (5minutes) (Arm 2) * if in Arm 1, participants will commence SOF-VEL DAA treatment after receiving an RNA test to confirm current hepatitis C infection. They will then continue along the treatment pathway, returning for RNA testing 4-16 weeks after SVR12 to determine cure. * if in Arm 2, participants will begin SOF-VEL DAA treatment on the same day as the 5 minute RDT testing. They will then continue along the treatment pathway, returning for RNA testing 4-16 weeks after SVR12 to determine cure. Researchers will compare cure and participant retention rates between the two groups.
Conditions
- Hepatitis C
- RDT
Interventions
sofosbuvir/velpatasvir (SOF/VEL)Drug
400mg of SOF and 100mg of VEL self administered daily as a tablet.
Shortened read time of rapid diagnostic test for hepatitis C virus.Diagnostic test
Administered once during hepatitis C testing. Test is read after 5 minutes rather than its usual time of 20 minutes.
Primary outcomes
What the sponsor says the trial is designed to measure.
- The feasibility of implementing a hepatitis C simplified care (Arm 1) and same-day treatment (Arm 2) care models in community and harm reduction settings in the three study countries.Time frame: 3 years
- The proportion of participants initiating hepatitis C treatment in simplified care Arm vs same-day treatment Arm.Time frame: 3 years
- The proportion of participants who achieve SVR following hepatitis C treatment in simplified care Arm vs same-day treatment Arm.Time frame: 3 years
- The comparative cost and cost-effectiveness of simplified care vs same-day treatment models of care.Time frame: 3 years
Locations
1 site in 1 country. Site status is shown where the registry gives one.
National Institute for Infectious Diseases
Yerevan, Armenia · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.